帕金森病

Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002.

• 全文
• 摘要

Gelb, DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33-39.

• 摘要

Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord. 2010;25:149-156.

• 摘要

Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11-17.

• 全文
• 摘要

Suchoversky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology). Neurology. 2006;66:976-982.

• 全文
• 摘要

Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009;24:647-654.

• 摘要

Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:924-931.

• 全文
• 摘要

Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7):CD007166.

• 全文
• 摘要

Talati R, Reinhart K, Baker W, et al. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord. 2009;15:500-505.

• 摘要

Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995.

• 全文
• 摘要

1.  Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland, 1817.

• 全文
• 摘要

2.  De Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry. 1997;62:10-15.

• 全文
• 摘要

3.  Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology. 1993;12:195-208.

• 摘要

4.  Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999;52:1214-1220.

• 摘要

5.  Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1-14.

• 摘要

6.  Rosati G, Graniere E, Pinna L, et al. The risk of Parkinson disease in Mediterranean people. Neurology. 1980;32:250-255.

• 摘要

7.  Quinn N, Crtichley P, Marsden CD. Young onset Parkinson's disease. Mov Disord. 1987;2:73-91.

• 摘要

8.  Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984;16:278-282.

• 摘要

9.  de Rijk MC. Epidemiology of Parkinson's disease: the Rotterdam Study [PhD thesis]. Rotterdam, The Netherlands: Erasmus University; 1997.

10.  Diamond SG, Markham CH, Hoehn MM, et al. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 1990;40:763-766.

• 摘要

11.  Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583-1590.

• 摘要

12.  McInerney-Leo A, Gwinn-Hardy K, Nussbaum RL. Prevalence of Parkinson's disease in populations of African ancestry: a review. J Natl Med Assoc. 2004;96:974-979.

• 摘要

13.  Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281:341-346.

• 全文
• 摘要

14.  Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361:1651-1661.

• 全文
• 摘要

15.  Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132:1783-1794.

• 全文
• 摘要

16.  Oueslati A, Ximerakis M, Vekrellis K. Protein transmission, seeding and degradation: key steps for alpha-synuclein prion-like propagation. Exp Neurobiol. 2014;23:324-336.

• 全文
• 摘要

17.  Wichmann T, DeLong MR. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol. 2003;91:9-18.

• 摘要

18.  Jankovic J, Ben-Arie L, Schwartz K, et al. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999;14:57-62.

• 摘要

19.  Vingerhoets FJ, Schulzer M, Calne DB, et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol. 1997;41:58-64.

• 摘要

20.  Dostrovsky JO, Hutchinson WD, Lozano AM. The globus pallidus, deep brain stimulation and Parkinson's disease. Neuroscientist. 2002;8:284-290.

• 摘要

21.  Tatton WG, Lee RG. Evidence for abnormal long-loop reflexes in rigid Parkinsonian patients. Brain Res. 1975;100:671-676.

• 摘要

22.  Horak FB, Nutt JG, Nashner LM. Postural inflexibility in parkinsonism subjects. J Neurol Sci. 1992;111:46-58.

• 摘要

23.  Hedreen JC. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J Comp Neurol. 1999;409:400-410.

• 摘要

24.  Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997 Sep;42(3):292-9.

• 摘要

25.  Lee RG, Stein RB. Resetting of tremor by mechanical perturbations: a comparison of essential tremor and parkinsonian tremor. Ann Neurol. 1981;10:523-531.

• 摘要

26.  Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.

• 摘要

27.  Braak H, de Vos RA, Bohl J, et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006;396:67-72.

• 摘要

28.  Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006;32:284-295.

• 摘要

29.  Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045-2047.

• 摘要

30.  Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605-608.

• 摘要

31.  Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395:451-452.

• 摘要

32.  Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.

• 摘要

33.  Mena I, Marin O, Fuenzalida S, et al. Chronic manganese poisoning: Clinical pictures and manganese turnover. Neurology. 1967;17:128-136.

• 摘要

34.  Dekker MC, Giesbergen PC, Njajou OT, et al. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci Lett. 2003;348:117-119.

• 摘要

35.  Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology. 1996;47:155-160.

• 摘要

36.  Bower JH, Maraganore DM, Peterson BJ, et al. Head trauma preceding PD: a case-control study. Neurology. 2003;60:1610-1615.

• 摘要

37.  Goldman SM, Tanner CM, Oakes D, et al. Head injury and Parkinson's disease risk in twins. Ann Neurol. 2006;60:65-72.

• 摘要

38.  Schoenberg BS. Environmental risk factors for Parkinson's disease: the epidemiologic evidence. Can J Neurol Sci. 1987;14(3 suppl):407-413.

• 摘要

39.  Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol. 2012;71:776-784.

• 摘要

40.  Gorell JM, Johnson CC, Rybicki BA, et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;42:1346-1350.

• 摘要

41.  Bocchetta A, Corsini GU. Parkinson's disease and pesticides. Lancet. 1986;2:1163.

• 摘要

42.  Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson's disease. Neurology. 1987;37:728.

• 摘要

43.  Barbosa ER, Leiros da Costa MD, Bacheschi LA, et al. Parkinsonism after glycine-derivate exposure. Mov Disord. 2001;16:565-568.

• 摘要

44.  Schulte PA, Burnett CA, Boeniger MF, et al. Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Am J Public Health. 1996;86:1281-1288.

• 全文
• 摘要

45.  Herishanu YO, Medvedovski M, Goldsmith JR, et al. A case-control study of Parkinson's disease in urban population of southern Israel. Can J Neurol Sci. 2001;28:144-147.

• 摘要

46.  Fall PA, Fredrikson M, Axelson O, et al. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord. 1999;14:28-37.

• 摘要

47.  Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30:1591-1601.

• 摘要

48.  Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002.

• 全文
• 摘要

49.  Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004;56:173-181.

• 摘要

50.  Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5-12.

• 摘要

51.  Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013;20:16-34.

• 全文
• 摘要

52.  Strickland D. Rural environment and Parkinson's disease. In: Ebadi M, Pfeiffer R, eds. Parkinson's disease. Boca Raton, FL: CRC Press; 2005:63-71.

53.  Gelb, DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33-39.

• 摘要

54.  Deuschl G, Bain P, Brin M; Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord. 1998;13(suppl 3):2-23.

• 摘要

55.  Reiter E, Mueller C, Pinter B, et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative parkinsonism. Mov Disord. 2015;30:1068-1076.

• 摘要

56.  Mahlknecht P, Krismer F, Poewe W, et al. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. Mov Disord. 2017 Apr;32(4):619-623.

• 摘要

57.  Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord. 2010;25:149-156.

• 摘要

58.  Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57:1497-1499.

• 摘要

59.  Doty RL, Shaman P, Kimmelman CP, et al. University of Pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94:176-178.

• 摘要

60.  Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237-1244.

• 摘要

61.  Walter U, Niehaus L, Probst T, et al. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology. 2003;60:74-77.

• 摘要

62.  Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017 Jun;32(6):853-864.

• 全文
• 摘要

63.  Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964 Apr;10:333-59.

• 摘要

64.  Wenning GK, Ben-Shlomo Y, Hughes A, et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;68:434-440.

• 全文
• 摘要

65.  Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13: PCC.11r01190.

• 全文
• 摘要

66.  Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.

• 全文
• 摘要

67.  Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129-2170.

• 全文
• 摘要

68.  Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11-17.

• 全文
• 摘要

69.  Clarke CE, Patel S, Ives N, et al. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord. 2011;26:1187-1193.

• 摘要

70.  Suchoversky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology). Neurology. 2006;66:976-982.

• 全文
• 摘要

71.  Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009;24:647-654.

• 摘要

72.  Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:924-931.

• 全文
• 摘要

73.  Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other non-motor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004;52:784-788.

• 摘要

74.  Baillon S, Dennis M, Lo N, et al. Screening for depression in Parkinson's disease: the performance of two screening questions. Age Ageing. 2014;43:200-205.

• 全文
• 摘要

75.  Bega D, Wu SS, Pei Q, et al. Recognition and treatment of depressive symptoms in Parkinson's disease: the NPF Dataset. J Parkinsons Dis. 2014;4:639-643.

• 摘要

76.  Lima LO, Scianni A, Rodrigues-de-Paula F. Progressive resistance exercise improves strength and physical performance in people with mild to moderate Parkinson's disease: a systematic review. J Physiother. 2013;59:7-13.

• 摘要

77.  Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev. 2013;(9):CD002817.

• 全文
• 摘要

78.  Corcos DM, Robichaud JA, David FJ, et al. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013;28:1230-1240.

• 全文
• 摘要

79.  Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med. 2012;366:511-519.

• 全文
• 摘要

80.  Gao Q, Leung A, Yang Y, et al. Effects of Tai Chi on balance and fall prevention in Parkinson's disease: a randomized controlled trial. Clin Rehabil. 2014;28:748-753.

• 摘要

81.  Hackney ME, Earhart GM, et al. Effects of dance on movement control in Parkinson's disease: a comparison of Argentine tango and American ballroom. J Rehabil Med. 2009;41:475-481.

• 全文
• 摘要

82.  Bega D, Gonzalez-Latapi P, Zadikoff C, et al. A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease. Curr Treat Options Neurol. 2014;16:314.

• 摘要

83.  Allen NE, Sherrington C, Paul SS, et al. Balance and falls in Parkinson's disease: a meta-analysis of the effect of exercise and motor training. Mov Disord. 2011;26:1605-1615.

• 摘要

84.  Rao AK. Enabling functional independence in Parkinson's disease: update on occupational therapy intervention. Mov Disord. 2010;25(suppl 1):S146-S151.

• 摘要

85.  Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-1278.

• 摘要

86.  Hauser RA, Rascol O, Olanow W, et al. Effects of long-term rasagiline treatment on time to key PD milestones: results from the ADAGIO follow-up (AFU) study [abstract]. Mov Disord. 2014;29(suppl 1):655.

• 全文

87.  Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12:747-755.

• 全文
• 摘要

88.  Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7):CD007166.

• 全文
• 摘要

89.  Talati R, Reinhart K, Baker W, et al. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord. 2009;15:500-505.

• 摘要

90.  Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154-165.

• 摘要

91.  Schapira AH, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:216-224.

• 摘要

92.  Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995.

• 全文
• 摘要

93.  Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12:346-356.

• 摘要

94.  LeWitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord. 2014;29:75-82.

• 摘要

95.  Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20:1335-1340.

• 全文
• 摘要

96.  Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010;9:581-591.

• 全文
• 摘要

97.  National Medical Association. Deep brain stimulation better than best medical therapy for Parkinson disease. J Natl Med Assoc. 2009;101:490.

98.  Schuepbach WM, Rau J, Knudsen K, et al; EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368:610-622.

• 全文
• 摘要

99.  Lyons KE, Pahwa R. Deep brain stimulation in Parkinson’s disease. Curr Neurol Neurosci Rep. 2004;4:290-295.

• 摘要

100.  Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010;362:2077-2091.

• 摘要

101.  Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141-149.

• 摘要

102.  Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015;30:500-509.

• 全文
• 摘要

103.  Mínguez-Mínguez S, Solís-García Del Pozo J, Jordán J. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. Pharmacol Res. 2013;74:78-86.

• 摘要

104.  Perez-Lloret S, Rey MV, Ratti PL, et al. Rotigotine transdermal patch for the treatment of Parkinson’s Disease. Fundam Clin Pharmacol. 2013;27:81-95.

• 摘要

105.  Zhou CQ, Li SS, Chen ZM, et al. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2013;8:e69738.

• 全文
• 摘要

106.  European Medicines Agency. CMDh confirms recommendations on restricting use of domperidone-containing medicines. April 2014. http://www.ema.europa.eu/ (last accessed 5 July 2017).

• 全文

107.  Lang AE, Houeto JL, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord. 2006;21(suppl 14):S171-S196.

• 摘要

108.  Lew MF, Somogyi M, McCague K, et al. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. Int J Neurosci. 2011;121:605-613.

• 摘要

109.  Pagan F, Hebron M, Valadez EH, et al. Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. J Parkinsons Dis. 2016 Jul 11;6(3):503-17.

• 全文
• 摘要

110.  Kefalopoulou Z, Politis M, Piccini P, et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 2014;71:83-87.

• 全文
• 摘要

111.  Snyder BJ, Olanow CW. Stem cell treatment for Parkinson's disease: an update for 2005. Curr Opin Neurol. 2005;18:376-385.

• 摘要

112.  Freese A, Stern M, Kaplitt MG, et al. Prospects for gene therapy in Parkinson's disease. Mov Disord. 1996;11:469-488.

• 摘要

113.  Nakata Y, Yasuda T, Mochizuki H. Recent progress in gene therapy for Parkinson's disease. Curr Mol Med. 2012;12:1311-1318.

• 摘要

114.  Jenner P. A2A antagonist as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology. 2003;61(suppl 6):S32-S38.

• 摘要

115.  Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70:2233-2240. [Erratum in: Neurology. 2008;71:953.]

• 摘要

116.  Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010;25:1437-1443.

• 摘要

117.  Mizuno Y, Kondo T; Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord. 2013;28:1138-1141.

• 全文
• 摘要

118.  Tison F, Keywood C, Wakefield M, et al. A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Mov Disord. 2016;31:1373-1380.

• 摘要

119.  Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord. 2013;28:1823-1831.

• 摘要

120.  Schwarzschild MA, Ascherio A, Beal MF, et al.; Parkinson Study Group SURE-PD Investigators. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71:141-150.

• 摘要

121.  LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov Disord. 2016;31:1356-1365.

• 摘要

122.  Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Mov Disord. 2016;31:1366-1372.

• 摘要

123.  Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83:328-335.

• 全文
• 摘要

124.  Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-844.

• 全文
• 摘要

125.  Velseboer DC, Broeders M, Post B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013;80:627-633.

• 摘要

126.  Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58:1611-1615.

• 全文
• 摘要

127.  Marras C, McDermott MP, Marek K, et al. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011;26:608-613.

• 摘要

128.  Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27:1230-1238.

• 摘要

129.  Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;(3):CD006504.

• 全文
• 摘要

130.  Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother. 2010;8:316-330.

• 摘要

131.  Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533-540.

• 摘要

132.  Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589-595.

• 全文
• 摘要